Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 62.27
(-1.16%)
CNY 62.27
(-1.16%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -214.22 Million CNY | 15.07% |
| 2022 | -402.2 Million CNY | -0.57% |
| 2021 | -405.55 Million CNY | -49.01% |
| 2020 | -256.62 Million CNY | 32.51% |
| 2019 | -405 Million CNY | 6.07% |
| 2018 | -437.35 Million CNY | -201.1% |
| 2017 | -141.38 Million CNY | -11.05% |
| 2016 | -129.19 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -40.52 Million CNY | 67.37% |
| 2024 Q2 | -35.98 Million CNY | 71.49% |
| 2024 Q3 | -26.66 Million CNY | -130.74% |
| 2023 Q4 | -124.19 Million CNY | -30.94% |
| 2023 FY | - CNY | 15.07% |
| 2023 Q3 | -94.85 Million CNY | -67.3% |
| 2023 Q2 | -56.69 Million CNY | -0.9% |
| 2023 Q1 | -56.19 Million CNY | 39.87% |
| 2022 FY | - CNY | -0.57% |
| 2022 Q3 | -121.4 Million CNY | 8.72% |
| 2022 Q2 | -133 Million CNY | -3.32% |
| 2022 Q1 | -128.73 Million CNY | 15.12% |
| 2022 Q4 | -93.45 Million CNY | 23.02% |
| 2021 Q2 | -100.32 Million CNY | -20.11% |
| 2021 Q1 | -83.52 Million CNY | 20.93% |
| 2021 FY | - CNY | -49.01% |
| 2021 Q4 | -151.66 Million CNY | -23.15% |
| 2021 Q3 | -123.15 Million CNY | -22.75% |
| 2020 Q4 | -105.63 Million CNY | -58.41% |
| 2020 Q3 | -66.68 Million CNY | -8.45% |
| 2020 Q1 | -74.65 Million CNY | -39.86% |
| 2020 FY | - CNY | 32.51% |
| 2020 Q2 | -61.49 Million CNY | 17.63% |
| 2019 FY | - CNY | 6.07% |
| 2019 Q4 | -53.37 Million CNY | 10.38% |
| 2019 Q3 | -59.55 Million CNY | 52.11% |
| 2019 Q2 | -124.37 Million CNY | 26.09% |
| 2019 Q1 | -168.29 Million CNY | 50.95% |
| 2018 Q4 | -343.12 Million CNY | 0.0% |
| 2018 FY | - CNY | -201.1% |
| 2017 FY | - CNY | -11.05% |
| 2016 FY | - CNY | 0.0% |